Home › Compound Library › DIM (Diindolylmethane)

DIM (Diindolylmethane)

Polyphenoloral · inferred

Acid-condensation product of indole-3-carbinol (I3C), derived from cruciferous vegetables. Modulates estrogen metabolism by shifting the 2-hydroxyestrone:16-alpha-hydroxyestrone ratio toward the less estrogenic 2-OHE1 pathway. Popular with TRT users for estrogen management as an alternative/complement to aromatase inhibitors. Also has anti-proliferative activity in estrogen-sensitive tissues. Enhanced bioavailability formulations (BioResponse DIM) dramatically improve absorption.

Projected serum levels — 200 mg, once daily

DIM (Diindolylmethane)
DIM (Diindolylmethane) modeled serum levels, 200 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 5 10 15 20 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 200 mg once daily (oral).

Modeled steady state after ~1 days: peak ≈ 10.2 mg, trough ≈ 0.048 mg body load. Population-based estimate over 15 days for a 200 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Polyphenol
Route modeled
Oral
Model confidence
inferred
Half-life
2.5 h
Common dose
200 mg
Suggested maximum
400 mg/day
Reference dose range
100–400 mg (single dose)
Suggested cadence
once daily
Validated against
300 mg oral — Cmax 0.10 mg/L at 2.5 h

Documented interactions

  • danger
    Efavirenz (Sustiva) + DIM (Diindolylmethane) CYP induction

    Efavirenz (Sustiva) inducer of CYP3A4 predicted to change DIM (Diindolylmethane) AUC by ~0.39x

  • danger
    Pseudoephedrine (Sudafed) + DIM (Diindolylmethane) CYP induction

    DIM (Diindolylmethane) inducer of CYP1A2 predicted to change Pseudoephedrine (Sudafed) AUC by ~0.50x

  • danger
    Rasagiline (Azilect) + DIM (Diindolylmethane) CYP induction

    DIM (Diindolylmethane) inducer of CYP1A2 predicted to change Rasagiline (Azilect) AUC by ~0.50x

  • danger
    Rifampin + DIM (Diindolylmethane) CYP induction

    Rifampin inducer of CYP3A4 predicted to change DIM (Diindolylmethane) AUC by ~0.39x

  • danger
    Theacrine (TeaCrine) + DIM (Diindolylmethane) CYP induction

    DIM (Diindolylmethane) inducer of CYP1A2 predicted to change Theacrine (TeaCrine) AUC by ~0.50x

  • danger
    Tizanidine (Zanaflex) + DIM (Diindolylmethane) CYP induction

    DIM (Diindolylmethane) inducer of CYP1A2 predicted to change Tizanidine (Zanaflex) AUC by ~0.50x

Serum checks 119 modeled interaction pairings for dim (diindolylmethane) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Diindolylmethane supplementation and estrogen metabolism in postmenopausal women: a pilot study Dalessandri KM et al. · Nutrition and Cancer, 2004 DOI

    Pilot study demonstrating DIM 108 mg/day (BioResponse formulation) significantly increased urinary 2-OHE1:16alpha-OHE1 ratio within 30 days, confirming favorable estrogen metabolism shift in postmenopausal women.

  2. Absorption and pharmacokinetics of diindolylmethane following oral administration Reed GA et al. · Cancer Epidemiology, Biomarkers & Prevention, 2008 DOI

    Clinical PK study establishing DIM half-life of 2-3 hours after enhanced-bioavailability formulation, tmax of 2.5 hours, dose-proportional pharmacokinetics from 100-300 mg, and confirming poor absorption of unformulated…

2 published studies referenced in the app, each with a plain-language summary.